News + Font Resize -

Barrier Therapeutics to launch US Sales Organization
Princeton, NJ | Friday, May 6, 2005, 08:00 Hrs  [IST]

Barrier Therapeutics, Inc., a pharmaceutical company developing and commercializing products in the field of dermatology, plans for the creation of its US sales organization.

Barrier had announced the hiring of three senior executives for its commercial organization, including Stephen Miller, Vice President of Sales. Recently, Barrier has signed an agreement with Ventiv Health, Inc., a leading provider of sales, marketing and compliance solutions to pharmaceutical and biotechnology companies with significant experience in specialty pharmaceutical sales solutions and dermatology products.

Over the next three months Barrier plans to build a field sales organization in the United States that will include six Barrier Regional Managers and approximately 60 sales representatives, comprised of up to 20 who will be Barrier employees and at least 40 who will be Ventiv employees. Barrier has already recruited three experienced Regional Managers who will lead the hiring of the first 30 sales representatives. The Company plans to expand the sales organization to a full complement of 60 sales representatives upon approval of ZimycanT by the US FDA.

In conjunction with the launch of its own sales organization, Barrier signed an agreement with Ventiv for supplemental sales and marketing services. Under the agreement, Ventiv will provide a number of complementary services including sales information systems, fleet management, training and logistics as well as recruiting support for the Barrier field force and the Ventiv sales representatives, according to a company release.

Al Altomari, chief commercial officer of Barrier Therapeutics. "During 2005 Barrier will continue its transition into a commercial organization. Initially our sales organization will focus its efforts on Solagé (mequinol 2%, tretinoin 0.01%) Topical Solution which we acquired earlier this year. We are also continuing to prepare for the sales force expansion and the launch of Zimycan, pending FDA approval later this year. Our current plan is to have all 60 sales representatives be Barrier employees by next summer."

Post Your Comment

 

Enquiry Form